Skip to main content
Equibles
ALXO logo

ALXO · Alx Oncology Holdings Inc · Webcasts, Transcripts & Audio

Track ALXO — free

Use ALXO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALXO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.22 -0.08 (-6.15%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$192.21M
Shares
138.28M
Volume · Oct 2 2.26M Avg daily vol (3M) 1.05M

Alx Oncology Holdings Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Alx Oncology Holdings Inc (ALXO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Conference
Investor event
2026-09-14
Alx Oncology Holdings Inc (ALXO) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Alx Oncology Holdings Inc (ALXO) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Alx Oncology Holdings Inc (ALXO) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-08
Alx Oncology Holdings Inc (ALXO) Q1 2026 Earnings Call Transcript
Confident tone EVO + zanidatumab HER2-positive breast cancer data (ESMO) CD47 biomarker predictive value ALX 2004 EGFR-targeted ADC program
Diluted EPS
$-0.17
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-27
Alx Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Transcript
Confident tone CD47 biomarker validation across HER2-positive tumors Phase II ASPEN-09 breast cancer trial ALX 2004 EGFR ADC dose escalation
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-07
Alx Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Transcript
Confident tone Avorpicept development strategy / targeted IO positioning ASPEN-06 / CD47 biomarker data in gastric cancer ALX2004 EGFR-targeted ADC
Diluted EPS
$-0.41
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Alx Oncology Holdings Inc (ALXO) Q2 2025 Earnings Call Transcript
Confident tone CD47 as predictive biomarker for evorpacept ASPEN-06 trial data and response rates Breast cancer program redesign
Diluted EPS
$-0.49
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Alx Oncology Holdings Inc (ALXO) Q1 2025 Earnings Call
Diluted EPS
$-0.58
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Alx Oncology Holdings Inc (ALXO) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Alx Oncology Holdings Inc (ALXO) Q3 2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–10 of 10 webcasts
Key facts CIK 1810182 CUSIP 00166B105 13F (30d) 2 filings 2 filers Visit website Investor relations